The elevated expression levels of CHEK1 point to a dependence on ATR/CHK1 and may suggest a particularly high vulnerability of SCLC tumors to inhibitors targeting the ATR/CHK1 signaling pathway (Fig. 1E). This evidence concerns the gene ATR and small cell lung carcinoma.